Glenmark gets USFDA nod for generic skin ointment
New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Desonide Ointment, used to treat skin problems, in the American market.
Glenmark Pharmaceuticals Inc, a subsidiary of the company, has received final approval from the US Food and Drug Administration (USFDA) for Desonide ointment, the company said in a statement.
The Mumbai-based company's product is the generic version of Perrigo New York Inc's Desonide Ointment.
As per the latest IMS Health sales data, the product had annual sales of around USD 23.4 million.
Glenmark s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDAs pending approval with the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd